Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509029 | 0.88 | FBP1 (0.42) | ALDH1A1HSD17B10FBP1POLBL3MBTL1 | |
| SCHEMBL3400531 | 0.86 | FBP1 (0.39) | ALDH1A1HSD17B10FBP1GAAMAPK1 | |
| SCHEMBL3405599 | 0.86 | HSP90B1 (0.38) | ALDH1A1GAA | |
| SCHEMBL1554027 | 0.83 | ALDH1A1 (0.42) | ALDH1A1HSD17B10FBP1POLBGAA | |
| SCHEMBL403488 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HSD17B10FBP1POLBGAA | |
| SCHEMBL3405279 | 0.73 | DGAT1 (0.38) | ALDH1A1HSD17B10KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL404952 | 0.73 | ALDH1A1 (0.58) | ALDH1A1HSD17B10FBP1GAACYP1A2 | |
| SCHEMBL509688 | 0.73 | ALDH1A1 (0.42) | ALDH1A1HSD17B10FBP1POLBGAA | |
| SCHEMBL4670943 | 0.72 | SMN1; SMN2 (0.37) | ALDH1A1CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL13070796 | 0.70 | ALDH1A1 (0.40) | ALDH1A1POLBGAAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-20100286181-A1 | PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| CN-101558066-A | Pyrrole derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2009-10-14 | — | — | CN | disclosed |
| EP-2064209-A1 | PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008020222-A1 | PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286181-A1 | PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | PGLS, UROD, GMPS | ALDH1A1 1828/4885HSD17B10 3158/4885FBP1 1324/4885 |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | ALDH1A1 243/4885HSD17B10 4653/4885FBP1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.